SCHEMBL3950907

SCHEMBL3950907

N#Cc1ccc2ccc[c]c2n1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SOS2 Q07890 1/20 0.44
SRC P12931 1/20 0.36
NQO1 P15559 1/20 0.35
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20264922 0.72 NQO1 (0.38) SOS2NQO1
SCHEMBL1071858 0.71 CYP1A2 (0.46)
SCHEMBL16049760 0.69
SCHEMBL3955189 0.69 CYP2A6 (0.33)
SCHEMBL4358400 0.69 METAP2 (0.31)
SCHEMBL4851470 0.69 CYP3A4 (0.30)
SCHEMBL3282411 0.69 NCF1 (0.45)
SCHEMBL75226 0.67 GRM5 (0.53) SOS2SRCNQO1
SCHEMBL29359679 0.67 GRM5 (0.53) SOS2SRCNQO1
SCHEMBL27416745 0.67 GRM5 (0.53) SOS2SRCNQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 US disclosed
US-7507732-B2 Cyclopentapyridine and tetrahydroquinoline derivatives PFIZER INC. (US) 2009-03-24 US disclosed
US-20060247254-A1 Cyclopentapyridine and tetrahydroquinoline derivatives PFIZER. INC 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 SOS2 4496/4885SRC 3966/4885NQO1 578/4885
US-20060247254-A1 Cyclopentapyridine and tetrahydroquinoline derivatives HTR2C, HTR2A, HTR5A SOS2 1651/4885SRC 3892/4885NQO1 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.